$433.00
Chromogenic method for the in vitro quantitative determination of Factor VIII (FVIII) activity, in human citrated plasma or FVIII concentrates, using an automated method.
Product Description
Kit
Chromogenic method for the in vitro quantitative determination of Factor VIII (FVIII) activity, in human citrated plasma or FVIII concentrates, using an automated method.
Product Characteristics
R1: Bovine Factor X at approximately 7.5 µg/mL, lyophilized. Contains a fibrin polymerization inhibitor, BSA and stabilizers.
R2: Activation Reagent, human Factor IIa at approximately 1 NIH/mL, human Factor IXa at approximately 2 µg/mL and synthetic Phospholipids (1:40 dilution), lyophilized. Contains BSA, Calcium Chloride Dihydrate and stabilizers.
R3: SXa-11, chromogenic substrate specific to Factor Xa (CS-11(32)) at approximately 6 mg/mL, lyophilized. Contains stabilizers and EDTA disodium salt.H373: May cause damage to organs through prolonged or repeated exposure.
R4: Tris-BSA Buffer, liquid. Contains BSA, human acid glycoprotein (AGP), stabilizers and preservatives.
Product Components
Product Application
Chromogenic method for the in vitro quantitative determination of Factor VIII (FVIII) activity, in human citrated plasma or FVIII concentrates, using an automated method.This method is for the detection of FVIII deficiency states and monitoring of replacement therapy (except Emicizumab) on patients who are suspected of congenital or acquired deficiency and potency estimation of FVIII concentrates.This device of in vitro diagnostic use is intended for professional use in the laboratory.
Related Products
